These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 39298592)

  • 1. The prion principle and Alzheimer's disease.
    Walker LC; Jucker M
    Science; 2024 Sep; 385(6715):1278-1279. PubMed ID: 39298592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The engineered peptide construct NCAM1-Aβ inhibits fibrillization of the human prion protein (PrP).
    Gielnik M; Zhukova L; Zhukov I; Gräslund A; Kozak M; Wärmländer S
    Acta Biochim Pol; 2022 Feb; 69(1):257-261. PubMed ID: 35143147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How an Infection of Sheep Revealed Prion Mechanisms in Alzheimer's Disease and Other Neurodegenerative Disorders.
    Carlson GA; Prusiner SB
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Abundance and Subverted Functions of Proteins in Prion-Like Diseases: Gained Functions Fascinate but Lost Functions Affect Aetiology.
    Allison WT; DuVal MG; Nguyen-Phuoc K; Leighton PLA
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases.
    Morales R; Estrada LD; Diaz-Espinoza R; Morales-Scheihing D; Jara MC; Castilla J; Soto C
    J Neurosci; 2010 Mar; 30(13):4528-35. PubMed ID: 20357103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability analysis of a steady state of a model describing Alzheimer's disease and interactions with prion proteins.
    Helal M; Igel-Egalon A; Lakmeche A; Mazzocco P; Perrillat-Mercerot A; Pujo-Menjouet L; Rezaei H; Tine LM
    J Math Biol; 2019 Jan; 78(1-2):57-81. PubMed ID: 30099569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases?
    Ritchie DL; Barria MA
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33540845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease?
    Willbold D; Kutzsche J
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31208037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.
    Wischik CM; Schelter BO; Wischik DJ; Storey JMD; Harrington CR
    J Alzheimers Dis; 2018; 62(3):1287-1303. PubMed ID: 29226873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches.
    Soto C
    J Mol Med (Berl); 1999 May; 77(5):412-8. PubMed ID: 10426190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.
    Crestini A; Santilli F; Martellucci S; Carbone E; Sorice M; Piscopo P; Mattei V
    J Alzheimers Dis; 2022; 85(2):503-518. PubMed ID: 34864675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggregation Condition-Structure Relationship of Mouse Prion Protein Fibrils.
    Fridmanis J; Toleikis Z; Sneideris T; Ziaunys M; Bobrovs R; Smirnovas V; Jaudzems K
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?
    Padilla-Zambrano HS; García-Ballestas E; Quiñones-Ossa GA; Sibaja-Perez AE; Agrawal A; Moscote-Salazar LR; Menéndez-González M
    Curr Alzheimer Res; 2020; 17(9):781-789. PubMed ID: 33280597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prion-Like Characteristics of Polyglutamine-Containing Proteins.
    Pearce MMP; Kopito RR
    Cold Spring Harb Perspect Med; 2018 Feb; 8(2):. PubMed ID: 28096245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins.
    Taylor DR; Hooper NM
    Semin Cell Dev Biol; 2007 Oct; 18(5):638-48. PubMed ID: 17822928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloidogenesis of Tau protein.
    Nizynski B; Dzwolak W; Nieznanski K
    Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Misfolding the way to disease.
    Taubes G
    Science; 1996 Mar; 271(5255):1493-5. PubMed ID: 8599100
    [No Abstract]   [Full Text] [Related]  

  • 18. Prion Diseases.
    Whitechurch BC; Welton JM; Collins SJ; Lawson VA
    Adv Neurobiol; 2017; 15():335-364. PubMed ID: 28674988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins.
    Marrero-Winkens C; Sankaran C; Schätzl HM
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32927676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid formation characteristics of GNNQQNY from yeast prion protein Sup35 and its seeding with heterogeneous polypeptides.
    Haratake M; Takiguchi T; Masuda N; Yoshida S; Fuchigami T; Nakayama M
    Colloids Surf B Biointerfaces; 2017 Jan; 149():72-79. PubMed ID: 27736724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.